Trastuzumab-Deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer (BC) after neoadjuvant therapy (NAT): a randomized, phase 3 trial (DESTINY-Breast05)

Authors :: E Mathias
Yibin Wang
LA McLean
A Prat
Naoki Niikura
Priya Rastogi
S Loibl
Charles E. Geyer
M Untch
Source :: Senologie - Zeitschrift für Mammadiagnostik und -therapie.
Publication Year :: 2021
Publisher :: Georg Thieme Verlag KG, 2021.

Subjects :: Oncology
medicine.medical_specialty
High risk patients
business.industry
medicine.medical_treatment
chemistry.chemical_compound
chemistry
Nat
Trastuzumab emtansine
Trastuzumab
Internal medicine
Medicine
business
Neoadjuvant therapy
Early breast cancer
medicine.drug

Tools